2. Геппе Н.А. и др. Острые инфекции дыхательных путей у детей. Диагностика, лечение, профилактика: клиническое руководство. 2-е изд. М., 2020. 254 с.

3. Иванова Н.А. Рецидивирующая обструкция бронхов и бронхиальная астма у детей первых пяти лет жизни. Российский вестник перинатологии и педиатрии. 2016;61(5):64–9.

4. Юренев Г.Л., Юренева-Тхоржевская Т.В. Бронхообструктивный синдром при острых респираторных вирусных инфекциях: причины и последствия. Практическая пульмонология. 2014;1:22–9.

5. Harris M., Clark J., Coote N., et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl.):2–23. Doi: 10.1136/thoraxjnl-2011-200598.

6. Дронов И.А., Малахов А.Б. Антибактериальная терапия при острых респираторных инфекциях у детей. Педиатрия. Consilium Medicum. 2017;4:31–5.

7. Morice A., Kardos P. Comprehensive evidence-based review on European antitussives. BMJ. Open Respir. Res. 2016;3(1):e000137. Doi: 10.1136/bmjresp-2016-000137.

8. Сhang A.B., Oppenheimer J.J., Weinberger M.M., et al. CHEST Expert Cough Panel. Chest. 2017;151(4):884–90. Doi: 10.1016/j.chest.2017.01.025.

9. Alyn H. Morice, Eva Millqvist, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. Doi: 10.1183/13993003.01136-2019.

10. Thompson M., Vodicka T.A., Blair P.S., et al. TARGET Programme Team. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ. 2013;347:f7027. Doi: 10.1136/bmj.f7027.

11. Kardos P., Schütt T., Mück T., et al. Pathophysiological Factors In The Relationship Between Chronological Age And Calculated Lung Age As Detected In A Screening Setting In Community-Dwelling Subjects. Front Med. 2016;3:2. Doi: 10.3389/Fmed.2016.00002.

12. Anderson-James S., Newcombe P.A., Marchant J.M., et al. An acute cough-specific quality-of-life questionnaire for children: development and validation. J Allergy Clin Immunol. 2015;135:1179–85.E1174. Doi: 10.1016/J.Jaci.2014.08.036

13. Jiang B., Chen J.-L., Lou H.-G. et al. Pharmacokinetic and bioequivalence study of three oral formulations of Ambroxol 30 mg: a randomized, three-period crossover comparison in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52:920–26. Doi: 10.5414/CP202156.

14. Чучалин А.Г., Абросимов В.Н. Кашель. М., 2016. 160 с.

15. Самсыгина Г.А. Кашель у детей. Клиническое руководство. М., 2016. 160 c.

16. Jason L.P., Galeb A.A., Curtis H. The healthy human microbiome. Genome Med. 2016;8:51.

17. Геппе Н.А., Озерская И.В., Малявина У.С. Цилиарный эпителий при респираторных вирусных инфекциях у детей. Влияние лекарственных препаратов. Русский медицинский журнал. 2012;20(24):1222–27.

18. Seto W.H., Conly J.M., Pessoa-Silva C.L., et al. Infection prevention and control measures for acute respiratory infections in health care settings: an update. East Mediterr Health J. 2013;19(Suppl. 1):39–47.

19. Balsamo R., Lanata L., Egan C.G. Mucoactive drugs. Eur Respir Rev. 2010;19(116):127–33. Doi: 10.1183/09059180.00003510.

20. Старостина Л.С. Варианты муколитической терапии кашля у детей. Русский медицинский журнал. 2019;3:60–4.

21. Disse B.G. The pharmacology of ambroxol -review and new results. Eur J Respir Dis. 1987;153(Suppl.):255–62.

22. Glowania A., Böhm M., Knopf A., Klimek L. The surfactant system – a new approach for treating the upper respiratory tract mucosa. Atemwegs Lungenkrankh. 2011;37:S1–5.

23. European Medicine Agencies. Revised assessment report: Ambroxol and bromhexine containing medicinal products 2015. URL: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-pracassessment-report_en.pdf.

24. Morgenroth K., Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration. 1985;47:225–31. Doi: 10.1159/000194774.

25. Fois G., Hobi N., Felder E., et al. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores. Cell Calcium. 2015;58:628–37. Doi: 10.1016/j.ceca.2015.10.002.

26. Kanie S., Yokohira M., Yamakawa K., et al. Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats. J Toxicol. 2017;30(2):153–15.

27. Shui-juan Zhang, Juan-xia Jiang, Qian-qian Ren, et al Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. Eur J Pharmacol. 2016;775:138–48. Doi: 10.1016/j.ejphar.2016.02.030.

28. Seagrave J., Albrecht H.H., Hill D.B., et al. G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir Res. 2012;13(1):98. Doi: 10.1186/1465-9921-13-98.

29. Paleari D., Rossi G.A., Nicolini G., Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 2011;6:1203–14. Doi: 10.1517/17460441.2011.629646.

30. Olivieri D., Zavattini G., Tomasini G., et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Respiration. 1987;51(Suppl. 1):42–51. Doi: 10.1159/000195274.

31. Cegla U.H. Long-term therapy over 2 years with Ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Prax Сlin Pneumol. 1988;42:715–21.

32. Matthys H., De Mey C., Carls C., et al. Efficacy and tolerability of Myrtol standardized in acute bronchitis. A multi-Centre, randomised, double-blind, placebo-controlled parallel group trial vs. cefuroxime and Ambroxol. Arzneimittelforschung. 2000;50:700–11. Doi: 10.1055/s-0031-1300276.

33. Du X., Zhao C., Liu S., Su S. Value of ambroxol in the treatment of asthmatic bronchitis. Pak J Med Sci. 2020;36 (3):501–4. Doi: 10.12669/pjms.36.3.1607.

34. Stetinová V., Herout V., Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med. 2004;4(3):152–58. Doi: 10.1007/s10238-004-0050-3.

35. Moretti M., Marchioni C.F. An overview of erdosteine antioxidant activity in experimental re-search. Pharmacol Res. 2007;55(4):249–54. Doi: 10.1016/j.phrs.2006.12.006.

36. Takeda K., Miyahara N., Matsubara S., et al. Immunomodulatory effects of Ambroxol on airway Hyperresponsiveness and inflammation. Immune Netw. 2016;16:165–75. Doi: 10.4110/In.2016.16.3.165.

37. Deretic V., Timmins G.S. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol. 2019;15:213–18. Doi: 10.1080/17425255.2019.1578748.

38. Basabe-Burgos O., Zebialowicz J., Stichtenoth G., et al. Natural derived surfactant preparation as a carrier of polymyxin E for treatment of Pseudomonas aeruginosa pneumonia in a near-term rabbit model. J Aerosol Med Pulm Drug Deliv. 2019;32:110–18. Doi: 10.1089/jamp.2018.1468.

39. Абатуров А.Е., Крючко Т.А. Антибиопленочная терапия при лечении респираторных инфекционных заболеваний, вызванных бактериальными патогенами. Zdorov’e rebenka. 2018;13(7):704–09.

40. Cataldi M., Sblendorio V., Leo A., Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 2014;28:98–108. Doi: 10.1016/j.pupt.2013.11.002.

41. Principi N., Zavattini G., Daniotti S. Possibility of interaction among antibiotics and mucolytics in children. Int J Clin Pharmacol Res 1986;6:369–72.

42. Chang C.C., Cheng A.C., Chang A.B. Over-the-counter medications to help reduce cough for children and adults on antibiotics for acute pneumonia. Cochrane Library Cochrane Database Syst. Rev. 2014 г. URL: https://www.cochrane.org/CD006088/ARI_over-the-counter-medications-to-help-reduce-cough-for-children-and-adults-on-antibiotics-for-acute-pneumonia.

43. Zuqin Yang, et al. Effects and mechanisms of ambroxol inhalation (Mucosolvan®) in the treatment of neonatal pneumonia. Pharmazie. 2017;72(10):604–7. Doi: 10.1691/ph.2017.7541.

44. Yang B., Yao D.F., Ohuchi M., et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002;19:952–58. Doi: 10.1183/09031936.02.00253302.

45. Li F., Yu J., Yang H., et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol. 2008;57:1–7. Doi: 10.1007/s00284-008-9142-8.

46. Yamaya M., Nishimura H., Lk N., et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37:520–29. Doi: 10.1007/S12272-013-0210-7.

47. Bradfute S.B., Ye C., Clarke E.C., et al. Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations. bioRxiv. 2020.08.11.245100. Doi: 10.1101/2020.08.11.245100.

48. Carpinteiro A., Gripp B., Hoffmann M., et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;296:100701. Doi: 10.1016/j.jbc.2021.100701.

49. Leffler A., Reckzeh J., Nau C. Block of sensory neuronal Na+ channels by the Secreolytic Ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010;630:19–28. Doi: 10.1016/J.Ejphar.2009.12.027.

50. De Mey C., Peil H., Kölsch S., et al. Efficacy and safety of Ambroxol lozenges in the treatment of acute uncomplicated sore throat. Arzneimittelforschung. 2008;58:557–68. d=Doi: 10.1055/S-0031-1296557.

51. Данные инструкций по медицинскому применению препаратов, содержащих амброксол. ГРЛС: (Электронный ресурс). These instructions for the medical use of drugs containing ambroxol. State Register of Medicines: (Electronic resource). (In Russ.)]. URL: https://grls.rosminzdrav.ru/grls.aspx (дата доступа / access date 08.10.2020).

52. Cazan D., Klimek L., Sperl A., et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018;17(12):1211–24. Doi: 10.1080/14740338.2018.1533954.

53. Малахов А.Б., Колосова Н.Г., Гребенева И.В. Выбор ингалятора (небулайзера) в клинической практике: вопросы и ответы. Педиатрия. Consilium Medicum. 2018;3:55–8.

54. Шахназарова М.Д., Геппе Н.А., Озерская И.В. и др. Современные возможности небулайзерной терапии в лечении респираторной патологии у детей. Фарматека. 2021;28(1):20–26.

55. Careddu P., Zavattini G. Mucosolvan® (Ambroxol) in paediatric use – Controlled clinical trial vs. acetylcysteine. Asthma Bronch Emphys. 1984;4:23–6.

56. Berni M., Collina A., Zavattini G. Ambroxol in bronchopulmonary pathology in children.

57. Baldini G., Gucci M., Tarò D., Memmini C. Controlled clinical study of a new ambroxol formulation in the treatment of infantile spastic bronchitis in children.

58. Malerba M., Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4:1119–29. Doi: 10.1517/17425255.4.8.1119.

59. Комитет по оценке рисков фармаконадзора (PRAC) Пересмотренный отчет об оценке: лекарственные средства, содержащие амброксол и бромгексин.